• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Seagen, Merck put $1.6B ADC collab on the back burner citing 'emerging treatment...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 03, 2023 at 06:42: PM
via Seagen is putting a phase 2 Merck & Co.-partnered antibody-drug conjugate on the shelf for now, nearly three years after signing on to a $1.6 billion partnership for the asset.

article source
 




Top Bottom
Back
Quote